Beneficial effects of *Monascus purpureus* NTU 568-fermented products on cholesterol *in vivo* and clinical trial: A review

Chien-Li Chen and Tzu-Ming Pan

1Research and Development Division, SunWay Biotech Co., Ltd., Taipei, Taiwan
2Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, Taiwan

**Abstract**

Red yeast rice (RYR) is prepared by fermenting rice with *Monascus*. RYR contains the compound monacolin K—the same active ingredient found in prescription cholesterol-lowering medications like lovastatin. Hypercholesterolemia is a dangerous form of cardiovascular disease, for which statins are generally prescribed as the main therapeutic drug. One of the most common complaints of people taking statins is muscle pain as a soreness, tiredness, weakness or induced rhabdomyolysis. The U.S. Food and Drug Administration has issued warnings that memory loss, mental confusion, neuropathy, high blood sugar, and type 2 diabetes are possible side effects. *Monascus purpureus* NTU 568-fermented product (Ankascin 568-R) contains monascin and ankaflavin as major active compounds, which was different from *Monascus* species fermented major compound monacolin K. Due to the high levels of *Monascus* metabolites and other ingredients, minimal amounts of Ankascin 568-R can be completely assimilated into the digestive system. Clinical results have showed statistically significant decreases of 11.9% and 19.0% were observed in total cholesterol and low-density lipoprotein cholesterol levels, respectively. This systematic review describes the applications, side effects, and health benefits of monacolin K, monascin, and ankaflavin in *Monascus*-fermented products based on animal studies and clinical trial. Empirical studies suggest that a potentially useful agent for the regulation of blood lipids and the treatment of coronary artery diseases.

**Introduction**

In Europe and the USA, more than 51% of total mortality is caused by cardiovascular diseases (including stroke, hypertension, and coronary heart disease) as a result of high blood cholesterol [1]. Monacolin K, also known as lovastatin, is a cholesterol-lowering compound produced by *Monascus*, it is the major active component in traditional red yeast rice (RYR) [2]. Statins can lead to myalgia (muscle pain), myopathy, elevated creatinine kinase (myonecrosis), and rhabdomyolysis [3]. The onset of myalgia varies from patient to patient, from a few weeks to years after the initiation of statin therapy [4]. In rhabdomyolysis, the release of intracellular muscle constituents due to muscle injury could lead to renal failure [5]. According to new safety updates, the FDA warned consumers to avoid cholesterol-lowering red mold rice (RMR) supplements promoted on the Internet [6] (RMR, RMR-policosanol complex, and Cholestrix), which may lead to myopathy and kidney dysfunction. The FDA does not recommend statin/monacolin K as dietary supplements owing to the risk of serious myopathies and rhabdomyolysis [7-9]. The increasing focus on evidence-based medicine, as well as the lack of studies and regulations to ensure the safety of these products have prompted skepticism among healthcare professionals regarding dietary supplements and herbal products that have otherwise proved to be safe and efficacious [10,11]. In this review, we describe a strain with promising health benefits, Ankascin’ 568-R, and summarize the effects of monascin (MS), ankaflavin (AK), and monacolin K (MK) based on animal models and a clinical study.

*Monascus purpureus* NTU 568 isolation and new functional ingredients

The red yeast strain *Monascus purpureus* NTU 568 has been isolated and studied for more than 10 years by the research team of Professor Tzu-Ming Pan (National Taiwan University). A new type of RYR (Ankascin 568-R), a product of fermentation by *Monascus purpureus* NTU 568 obtained by SunWay Biotech., Co., Ltd. (Taipei, ROC), contains high levels of two major active compounds, MS and AK. These yellow pigments are naturally produced by *Monascus* species.

**Beneficial effects of monascin (MS) and ankaflavin (AK) in cholesterol management**

We have previously shown that in hyperlipidemic hamsters, Ankascin 568-R has better hypolipidemic and antiatherosclerosis in addition to MK [12]. The yellow pigments MS/AK not only possess hypolipidemic functions reduced the total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels, with an inhibitory activity by 29.8% (MS)/28.6% (AK), 63.4% (MS)/58.2% (AK), and 33.9% (MS)/42.3% (AK), respectively, but also could increase high-density lipoprotein cholesterol (HDL-C) levels by 16.4% (MS)/20.9% (AK) [12,13], explaining the better hypolipidemic and HDL-C-elevating effects of Ankascin 568-R [13]. Hyperlipidemia refers to increased levels of lipids (fats) in the blood, including TC and TG. It...
can significantly increase the risk of cardiovascular disease, including diseases of blood vessels supplying the heart, brain, and limbs. These conditions can lead to chest pain, heart attacks, strokes, and other problems. Therefore, the management of hyperlipidemia requires the control of TC and TG.

Effects and side effects of monascin, ankaflavin, and monacolin K

We compared the hypolipidemic and anti-atherosclerosis effects of MS, AK, and MK under the same dosages, including analyses of side effects. MS and AK had similar effects to those of MK, i.e., they significantly reduced TC, TG, and LDL-C levels in the serum and plaque accumulation in the aorta. Although the reductions in serum TC and TG by AK and MK were similar, AK had more significant effects on the prevention of fatty liver and lipid plaque accumulation in the aorta than those of MK. More importantly, MS significantly enhanced HDL-C concentrations, while MK had the opposite effect [14]. With respect to side effects, we evaluated whether the interaction between Monascus-fermented products and lovastatin contributes to an increased risk of rhabdomyolysis. MK elevated creatine phosphokinase (CPK) activity, which is highly correlated with rhabdomyolysis development, while this side effect was not observed for MS and AK. Accordingly, MS and AK have the potential to be used as hypolipidemic agents, without increasing the risk of rhabdomyolysis. The administration of Ankascin 568-R alone or in combination with lovastatin did not cause significant rhabdomyolysis, as determined by the levels of CPK. Further, we did not find any study that clearly implicates Ankascin 568-R in liver and kidney toxicity [15].

Safety

Monascus-fermented products may be contaminated by citrinin, which could damage the kidneys and liver. Citrinin, a toxic secondary metabolite of certain fungi, was first isolated as a pure compound from \textit{Penicillium citrinum} in 1931 [16]. It is produced by various \textit{Penicillium}, \textit{Aspergillus}, and \textit{Monascus} species [17,18]. It is widely considered a hazardous contaminant of foods and feeds, including grains, fruits, and oil seeds [19]. As citrinin poses a risk to human health, many countries and scientific committees have established maximum levels for food [20]. However, according to Sánchez et al. [21] in an EPA report, there are insufficient data to determine the upper limits of daily exposure to citrinin for humans and animals. Animals and humans are exposed to citrinin by the consumption of contaminated food, inhalation, and skin contact [22]. Evaluations of Monascus-fermented products for an experimental period of as long as four months have shown no toxicity [23]. Recent studies have confirmed that Monascus-fermented products do not have adverse health effects, and the control of the citrinin concentration in Monascus-fermented products is an important issue [24]. Increasing the concentration of MK and decreasing the concentration of citrinin have been evaluated by several laboratories [25-27]. Various citrinin concentrations (1, 2, 10, 20, and 200 ppm) in RMR have been evaluated for safety in animal tests [28]. In a 90-day animal test, the no-observable-adverse-effect level (NOAEL) was 200 ppm citrinin for male Wistar rats. The safe concentration of citrinin in Monascus-fermented products is 2 ppm. Owing to the substantial concern regarding citrinin contamination, Japan has issued an advisory limit of 200 ppb; the current FDA action level in agricultural products on the market is 20 ppb citrinin, and the European Union has recommended a limit of 100 ppb. Recent investigations are focused on conditions for reducing the citrinin concentration in Monascus-fermented products during production.

Ankascin 568-R, containing monascin and ankaflavin, can regulate blood lipids and impact heart health (clinical trial)

The most common causes of heart disease, such as metabolic syndrome, involve several cardiovascular risk factors, such as central obesity, hyperglycemia, hypertension, and hyperlipidemia, which are pathogenically correlated. In a clinical study, 57 qualified subjects were initially enrolled and 17 were withdrawn owing to contraindicated diseases or sensory problems, for a total of 40 subjects assigned to test and placebo groups. The dietary behavior and lifestyle of the subjects did not change during the study and no clinical symptoms or discomfort were recorded. In addition, there were no differences in anthropometric measurements after eight weeks of intervention between the test and placebo groups. TC and LDL-C levels in the treatment group (500 mg of Ankascin 568 Plus/day, include Ankascin 568-R 110 mg) decreased significantly, by 11.9% and 19.0%, respectively. In the placebo group, TC and LDL-C levels only changed by 0.1% and 1.9%, respectively. Compared with levels in the placebo group, Ankascin 568 Plus can indeed reduce TC and LDL-C. The serum TG levels in the treatment and placebo groups at weeks 0, 4, 8, and 12 did not differ between the treatment and placebo groups. However, the TG values showed considerable variation among patients in each group. This intragroup variability might explain the lack of statistically significant differences between groups. Furthermore, LDL-C levels and the LDL-C/HDL-C ratio were significantly lower in the Ankascin 568 Plus-treated group than in the placebo group. LDL-C is a key indicator of coronary heart disease. It is an important lipoprotein cholesterol that can be transported to the body cells for use. However, high blood levels of LDL-C result in accumulation in the vessel walls, leading to atherosclerosis. Therefore, high LDL-C is considered a risk factor for vascular obstruction. In contrast, HDL-C is an essential substance for the prevention of atherosclerosis and is widely used to assess the incidence of coronary artery disease; low levels are an important predictor of coronary atherosclerosis. Ankascin 568 Plus regulates blood lipids and reduces cardiovascular disease. The administration of Ankascin 568 Plus had no significant effects on the metabolic or physiological function of the kidneys. These results clearly support the use of Ankascin 568 Plus for substantially reducing the risk of cardiovascular diseases [29].

Conclusions

Recent studies of RYR products contribute to improved food safety management by consumer protection authorities. Ankascin 568 Plus produced by \textit{M. purpureus} NTU 568 fermentation is a potentially useful agent for the regulation of blood lipids and the treatment of coronary artery diseases.

References

1. Benjamin EJ, Blaha MJ, Chiueh SE, Cushman M, Das SR, et al. (2017) Heart disease and stroke statistics—2017 update: A report from the American Heart Association. Circulation 135: e146-e603. [Crossref]
2. Lin YL, Wang TH, Lee MH, Su NW (2008) Biologically active components and nutraceuticals in the Monascus-fermented rice: a review. Appl Microbiol Biotechnol 77: 965–973. [Crossref]
3. Camerino GM, De Bellis M, Conte E, Liantonio A, Musaraj K, et al. (2016) Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. Toxicol Appl Pharmacol 306: 36-46. [Crossref]
4. Toubert JA (1988) Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62: 128–134. [Crossref]
5. Echaniz-Laguna A, Mohr M, Tranchant C (2010) Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 362: 564–565. [Crossref]
